Sialidosis is a hereditary lysosomal storage disorder, inherited in an autosomal recessive manner, caused by pathogenic variants in the NEU1 gene. These alterations reduce or abolish neuraminidase 1 activity, leading to the accumulation of sialylated oligosaccharides and glycopeptides in lysosomes, with variable involvement of the nervous system, retina, and other tissues.
Sialidosis
The NEU1 gene encodes neuraminidase 1 or lysosomal sialidase, an enzyme responsible for removing terminal sialic acid residues from glycoproteins, glycolipids, and oligosaccharides within lysosomes. This reaction allows for the complete degradation and recycling of complex macromolecules. To function stably, neuraminidase 1 is part of a lysosomal multienzyme complex along with other protective proteins.
When pathogenic variants exist in NEU1, residual enzyme activity decreases, and undegraded sialylated compounds accumulate in multiple tissues. The disease is considered a clinical spectrum that includes sialidosis type I, milder and with a later onset, also known as cherry-red spot and myoclonus syndrome; and sialidosis type II, with congenital, infantile, or juvenile onset, and more marked multisystem involvement. Inheritance is autosomal recessive, meaning the affected person must inherit an altered copy of the gene from each parent. It is an ultra-rare disease, with fewer than a few hundred described cases, without a clear global population predilection, although some recurrent variants have been described in specific groups.
Symptoms
The age of onset and severity depend on the subtype and residual enzymatic activity. Sialidosis type I usually appears in adolescence or early adulthood, with progressive myoclonus, ataxia, seizures, visual loss, and the characteristic macular cherry-red spot, generally without dysmorphic features or significant intellectual impairment. Sialidosis type II manifests earlier and can present with fetal hydrops or, in infants and children, coarse facial features, multiple dysostosis, hepatosplenomegaly, developmental delay, seizures, and ocular involvement. Diagnosis is supported by elevated sialylated oligosaccharides and confirmed by enzymatic and genetic studies.
Disease management
Currently, there is no curative treatment or approved enzyme replacement therapy for sialidosis. Management is symptomatic and multidisciplinary, with control of epileptic seizures and myoclonus, physical and occupational rehabilitation, visual support, orthopedic, respiratory, and nutritional monitoring when necessary, and surveillance of systemic complications.
In severe forms, treatment is aimed at preserving quality of life and preventing secondary complications. Strategies such as gene therapy, pharmacological chaperones, and substrate reduction are being investigated, but they are not yet part of standard clinical management.
Genes analyzed
Bibliography
Khan A, Sergi C. Sialidosis: A Review of Morphology and Molecular Biology of a Rare Pediatric Disorder. Diagnostics (Basel). 2018 Apr 25;8(2):29.
Ding Y, Cheng M, Gong C. Two cases of type I sialidosis and a literature review. Orphanet J Rare Dis. 2024 Nov 27;19(1):440.
Kılıç M, İcil S, Sezer A, et al. Sialidosis type 1 in a Turkish family: a case report and review of literatures. J Pediatr Endocrinol Metab. 2024 Dec 30;38(2):176-186.
Ahn JH, Kim AR, Lee C, et al. Type 1 Sialidosis Patient With a Novel Deletion Mutation in the NEU1 Gene: Case Report and Literature Review. Cerebellum. 2019 Jun;18(3):659-664.
Peng ML, Chau SF, Chien JY, et al. Genetic Insights and Clinical Implications of NEU1 Mutations in Sialidosis. Genes (Basel). 2025 Jan 25;16(2):151.
